{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:59:38Z","timestamp":1788303578951,"version":"build-2803163510"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.blre.2019.03.007","type":"journal-article","created":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T22:13:48Z","timestamp":1553897628000},"page":"23-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Eosinophilia in acute myeloid leukemia: Overlooked and underexamined"],"prefix":"10.1016","volume":"36","author":[{"given":"Leonard","family":"Naymagon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Marcellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.blre.2019.03.007_bb0005","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/ajh.24880","article-title":"World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management","volume":"92","author":"Gotlib","year":"2017","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.blre.2019.03.007_bb0010","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1182\/blood.V68.6.1242.1242","article-title":"Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis","volume":"68","author":"Larson","year":"1986","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2019.03.007_bb0015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.seminhematol.2015.04.002","article-title":"Core binding factor acute myeloid leukemia: new prognostic categories and therapeutic opportunities","volume":"52","author":"Sinha","year":"2015","journal-title":"Semin Hematol"},{"issue":"8","key":"10.1016\/j.blre.2019.03.007_bb0020","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.3324\/haematol.2017.187302","article-title":"Molecular genetic characterization of myeloid\/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2","volume":"103","author":"Baer","year":"2018","journal-title":"Haematologica"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2019.03.007_bb0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/10428199509075305","article-title":"AML M1 and M2 with eosinophilia and AML M4Eo: diagnostic and clinical aspects","volume":"18","author":"Loffler","year":"1995","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.blre.2019.03.007_bb0030","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3324\/haematol.11889","article-title":"M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience","volume":"93","author":"Pulsoni","year":"2008","journal-title":"Haematologica."},{"issue":"6","key":"10.1016\/j.blre.2019.03.007_bb0035","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1200\/JCO.2004.07.012","article-title":"Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461","volume":"22","author":"Byrd","year":"2004","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2019.03.007_bb0040","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","article-title":"Myeloid neoplasms with eosinophilia","volume":"129","author":"Reiter","year":"2017","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.blre.2019.03.007_bb0045","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2019.03.007_bb0050","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ajh.21631","article-title":"Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution","volume":"85","author":"Patnaik","year":"2010","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.blre.2019.03.007_bb0055","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1080\/10428194.2017.1397663","article-title":"Myeloid\/lymphoid neoplasms with FGFR1 rearrangement","volume":"59","author":"Strati","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.blre.2019.03.007_bb0060","doi-asserted-by":"crossref","first-page":"790","DOI":"10.6004\/jnccn.2017.0106","article-title":"Morphologic and molecular characteristics of De novo AML with JAK2 V617F mutation","volume":"15","author":"Hidalgo-Lopez","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.blre.2019.03.007_bb0065","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3343\/alm.2016.36.1.79","article-title":"A t(8;9)(p22;p24)\/PCM1-JAK2 translocation in a patient with myeloproliferative neoplasm and myeloid sarcoma: first report in Korea","volume":"36","author":"Song","year":"2016","journal-title":"Ann Lab Med"},{"issue":"5","key":"10.1016\/j.blre.2019.03.007_bb0070","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3343\/alm.2018.38.5.492","article-title":"PCM1-JAK2 fusion in a patient with acute myeloid leukemia","volume":"38","author":"Lee","year":"2018","journal-title":"Ann Lab Med"},{"issue":"8","key":"10.1016\/j.blre.2019.03.007_bb0075","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-03-343426","article-title":"Response of ETV6-FLT3-positive myeloid\/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3","volume":"118","author":"Walz","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2019.03.007_bb0080","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00277-016-2721-z","article-title":"BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features","volume":"95","author":"Neuendorff","year":"2016","journal-title":"Ann Hematol"},{"issue":"15","key":"10.1016\/j.blre.2019.03.007_bb0085","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJM199910073411503","article-title":"Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia","volume":"341","author":"Simon","year":"1999","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.blre.2019.03.007_bb0090","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJM198309153091103","article-title":"Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association","volume":"309","author":"Le Beau","year":"1983","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.blre.2019.03.007_bb0095","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/ajcp\/81.6.733","article-title":"A morphologic and cytochemical study of acute myelomonocytic leukemia with abnormal marrow eosinophils associated with inv(16)(p13q22)","volume":"81","author":"Bitter","year":"1984","journal-title":"Am J Clin Pathol"},{"issue":"22","key":"10.1016\/j.blre.2019.03.007_bb0100","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJM198312013092225","article-title":"Chromosome 16 and bone-marrow eosinophilia","volume":"309","author":"de la Chapelle","year":"1983","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.blre.2019.03.007_bb0105","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJM198402163100720","article-title":"Chromosome 16 rearrangements in acute myelomonocytic leukemia with abnormal eosinophils","volume":"310","author":"Testa","year":"1984","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2019.03.007_bb0110","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2141.2009.07746.x","article-title":"Acute myeloid leukaemia with associated eosinophilia: justification for FIP1L1-PDGFRA screening in cases lacking the CBFB-MYH11 fusion gene","volume":"146","author":"Sorour","year":"2009","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2019.03.007_bb0115","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.leu.2404662","article-title":"Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma","volume":"21","author":"Metzgeroth","year":"2007","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.blre.2019.03.007_bb0120","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood-2014-02-555607","article-title":"Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib","volume":"123","author":"Cheah","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2019.03.007_bb0125","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/leu.2013.129","article-title":"Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid\/lymphoid neoplasms with PDGFR rearrangements in blast phase","volume":"27","author":"Metzgeroth","year":"2013","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.blre.2019.03.007_bb0130","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","article-title":"Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness","volume":"101","author":"Klion","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.007_bb0135","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.12659\/AJCR.906300","article-title":"Acute lymphoblastic leukemia patient with variant ATF7IP\/PDGFRB fusion and favorable response to tyrosine kinase inhibitor treatment: a case report","volume":"18","author":"Zhang","year":"2017","journal-title":"Am J Case Rep"},{"issue":"18","key":"10.1016\/j.blre.2019.03.007_bb0140","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1182\/blood-2015-09-670166","article-title":"EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications","volume":"127","author":"Schwab","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2019.03.007_bb0145","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1038\/leu.2017.161","article-title":"Novel PDGFRB fusions in childhood B- and T-acute lymphoblastic leukemia","volume":"31","author":"Heilmann","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2019.03.007_bb0150","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/sj.leu.2404894","article-title":"A PDGFRB-positive acute myeloid malignancy with a new t(5;12)(q33;p13.3) involving the ERC1 gene","volume":"22","author":"Gorello","year":"2008","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2019.03.007_bb0155","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s12185-016-2167-z","article-title":"Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia","volume":"105","author":"Shimomura","year":"2017","journal-title":"Int J Hematol"},{"issue":"8","key":"10.1016\/j.blre.2019.03.007_bb0160","first-page":"789","article-title":"Clonal eosinophils are a morphologic hallmark of ETV6\/ABL1 positive acute myeloid leukemia","volume":"87","author":"La Starza","year":"2002","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.blre.2019.03.007_bb0165","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1182\/blood.V99.9.3465","article-title":"Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation","volume":"99","author":"O'Brien","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2019.03.007_bb0170","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000342490","article-title":"Variant of ETV6\/ABL1 gene is associated with leukemia phenotype","volume":"129","author":"Park","year":"2013","journal-title":"Acta Haematol"},{"issue":"9","key":"10.1016\/j.blre.2019.03.007_bb0175","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3324\/haematol.2016.144345","article-title":"Characterization of leukemias with ETV6-ABL1 fusion","volume":"101","author":"Zaliova","year":"2016","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.blre.2019.03.007_bb0180","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00277-016-2598-x","article-title":"Diagnostic challenges in the work up of hypereosinophilia: pitfalls in bone marrow core biopsy interpretation","volume":"95","author":"Schwaab","year":"2016","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.blre.2019.03.007_bb0185","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.5858\/arpa.2010-0482-RS","article-title":"Core-binding factor acute myeloid leukemia","volume":"135","author":"Sangle","year":"2011","journal-title":"Arch Pathol Lab Med"},{"issue":"12","key":"10.1016\/j.blre.2019.03.007_bb0190","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/ng.3709","article-title":"The genomic landscape of core-binding factor acute myeloid leukemias","volume":"48","author":"Faber","year":"2016","journal-title":"Nat Genet"},{"issue":"20","key":"10.1016\/j.blre.2019.03.007_bb0195","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2015-12-688705","article-title":"Comprehensive mutational profiling of core binding factor acute myeloid leukemia","volume":"127","author":"Duployez","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2019.03.007_bb0200","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1365-2141.2004.05158.x","article-title":"Activating loop mutations in the PDGFR alpha and beta genes are rare in core binding factor acute myeloid leukaemia","volume":"127","author":"Johan","year":"2004","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2019.03.007_bb0205","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1600-0609.2005.00543.x","article-title":"Molecular analysis of PDGFRalpha\/beta genes in core binding factor leukemia with eosinophilia","volume":"76","author":"Monma","year":"2006","journal-title":"Eur J Haematol"},{"issue":"13","key":"10.1016\/j.blre.2019.03.007_bb0210","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.blre.2019.03.007_bb0215","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2019.03.007_bb0220","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/10428194.2016.1197396","article-title":"The importance of cytogenetic and molecular analyses in eosinophilia-associated myeloproliferative neoplasms: an unusual case with normal karyotype and TNIP1- PDGFRB rearrangement and overview of PDGFRB partner genes","volume":"58","author":"Maccaferri","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.blre.2019.03.007_bb0225","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40364-016-0070-7","article-title":"A novel three-way rearrangement involving ETV6 (12p13) and ABL1 (9q34) with an unknown partner on 3p25 resulting in a possible ETV6-ABL1 fusion in a patient with acute myeloid leukemia: a case report and a review of the literature","volume":"4","author":"Tirado","year":"2016","journal-title":"Biomark Res"},{"issue":"8","key":"10.1016\/j.blre.2019.03.007_bb0230","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1128\/MCB.16.8.4107","article-title":"Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia","volume":"16","author":"Golub","year":"1996","journal-title":"Mol Cell Biol"},{"issue":"4","key":"10.1016\/j.blre.2019.03.007_bb0235","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2019.03.007_bb0240","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2353\/jmoldx.2007.060196","article-title":"A case of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia with a rare FIP1L1 breakpoint","volume":"9","author":"Lambert","year":"2007","journal-title":"J Mol Diagn"},{"issue":"5","key":"10.1016\/j.blre.2019.03.007_bb0245","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/ijlh.12057","article-title":"Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review","volume":"35","author":"Savage","year":"2013","journal-title":"Int J Lab Hematol"},{"issue":"5","key":"10.1016\/j.blre.2019.03.007_bb0250","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3324\/haematol.2009.016345","article-title":"Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis","volume":"95","author":"Erben","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.blre.2019.03.007_bb0255","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2019.03.007_bb0260","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1200\/JCO.1999.17.12.3767","article-title":"Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered","volume":"17","author":"Byrd","year":"1999","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.blre.2019.03.007_bb0265","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.blre.2019.03.007_bb0270","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/sj.leu.2403600","article-title":"Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia","volume":"19","author":"von Bubnoff","year":"2005","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2019.03.007_bb0275","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/leu.2009.2","article-title":"FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib","volume":"23","author":"Lierman","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.blre.2019.03.007_bb0280","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1200\/JCO.2009.23.6976","article-title":"Acute myeloid leukemia with myeloid sarcoma and eosinophilia: prolonged remission and molecular response to imatinib","volume":"28","author":"Vedy","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2019.03.007_bb0285","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1756-8722-7-26","article-title":"Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia","volume":"7","author":"Shah","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.blre.2019.03.007_bb0290","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00277-017-3067-x","article-title":"Imatinib in myeloid\/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase","volume":"96","author":"Jawhar","year":"2017","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.blre.2019.03.007_bb0295","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/sj.leu.2404728","article-title":"A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease","volume":"21","author":"Curtis","year":"2007","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.blre.2019.03.007_bb0300","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/leu.2012.8","article-title":"Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases","volume":"26","author":"Lierman","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.blre.2019.03.007_bb0305","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.exphem.2013.12.007","article-title":"Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA","volume":"42","author":"Sadovnik","year":"2014","journal-title":"Exp Hematol"},{"issue":"4","key":"10.1016\/j.blre.2019.03.007_bb0310","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2006-02-004457","article-title":"Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant","volume":"108","author":"Lierman","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2019.03.007_bb0315","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(03)00108-9","article-title":"PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease","volume":"3","author":"Cools","year":"2003","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.blre.2019.03.007_bb0320","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1158\/1078-0432.CCR-12-0625","article-title":"Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors","volume":"18","author":"Heinrich","year":"2012","journal-title":"Clin Cancer Res"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X18301188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X18301188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:23:00Z","timestamp":1759436580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X18301188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":64,"alternative-id":["S0268960X18301188"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2019.03.007","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eosinophilia in acute myeloid leukemia: Overlooked and underexamined","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2019.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}